Company intelligence / Profile preview
Avidity Biosciences
San Diego, California, United States of Americaaviditybiosciences.com ↗
- Ownership
- Public · RNA
- Employees
- ~391
- Development stage
- Phase 3
01
Overview
Avidity has three clinical programs for rare muscle diseases. Their lead candidate delpacibart etedesiran (del-desiran/AOC 1001) for DM1 has shown consistent and durable improvements in myotonia, muscle strength and activities of daily living in Phase 2 trials, with Phase 3 HARBOR trial accelerated to begin in Q2 2024. They plan to file their first BLA for delpacibart zotadirsen (del-zota) for DMD44 by the end of 2025, with accelerated approval path confirmed.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- RNA therapeuticsAntibody Oligonucleotide Conjugates (AOCs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Avidity Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avidity Biosciences.